Detail
Article
Online article
FT
Medvik - BMC
  • Something wrong with this record ?

Advanced MRI increases the diagnostic accuracy of recurrent glioblastoma: Single institution thresholds and validation of MR spectroscopy and diffusion weighted MR imaging

T. Kazda, M. Bulik, P. Pospisil, R. Lakomy, M. Smrcka, P. Slampa, R. Jancalek,

. 2016 ; 11 (-) : 316-321. [pub] 20160226

Language English Country Netherlands

Document type Journal Article, Research Support, Non-U.S. Gov't

Persistent link   https://www.medvik.cz/link/bmc18017207

Grant support
NT14120 MZ0 CEP Register
NT14600 MZ0 CEP Register

The accurate identification of glioblastoma progression remains an unmet clinical need. The aim of this prospective single-institutional study is to determine and validate thresholds for the main metabolite concentrations obtained by MR spectroscopy (MRS) and the values of the apparent diffusion coefficient (ADC) to enable distinguishing tumor recurrence from pseudoprogression. Thirty-nine patients after the standard treatment of a glioblastoma underwent advanced imaging by MRS and ADC at the time of suspected recurrence - median time to progression was 6.7 months. The highest significant sensitivity and specificity to call the glioblastoma recurrence was observed for the total choline (tCho) to total N-acetylaspartate (tNAA) concentration ratio with the threshold ≥ 1.3 (sensitivity 100.0% and specificity 94.7%). The ADCmean value higher than 1313 × 10(- 6) mm(2)/s was associated with the pseudoprogression (sensitivity 98.3%, specificity 100.0%). The combination of MRS focused on the tCho/tNAA concentration ratio and the ADCmean value represents imaging methods applicable to early non-invasive differentiation between a glioblastoma recurrence and a pseudoprogression. However, the institutional definition and validation of thresholds for differential diagnostics is needed for the elimination of setup errors before implementation of these multimodal imaging techniques into clinical practice, as well as into clinical trials.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18017207
003      
CZ-PrNML
005      
20241016141529.0
007      
ta
008      
180515e20160226ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.nicl.2016.02.016 $2 doi
035    __
$a (PubMed)27298760
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Kazda, Tomáš $u International Clinical Research Center, St. Anne's University Hospital Brno, 656 91 Brno, Czech Republic; Department of Radiation Oncology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic; Department of Radiation Oncology, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic. $7 xx0213412
245    10
$a Advanced MRI increases the diagnostic accuracy of recurrent glioblastoma: Single institution thresholds and validation of MR spectroscopy and diffusion weighted MR imaging / $c T. Kazda, M. Bulik, P. Pospisil, R. Lakomy, M. Smrcka, P. Slampa, R. Jancalek,
520    9_
$a The accurate identification of glioblastoma progression remains an unmet clinical need. The aim of this prospective single-institutional study is to determine and validate thresholds for the main metabolite concentrations obtained by MR spectroscopy (MRS) and the values of the apparent diffusion coefficient (ADC) to enable distinguishing tumor recurrence from pseudoprogression. Thirty-nine patients after the standard treatment of a glioblastoma underwent advanced imaging by MRS and ADC at the time of suspected recurrence - median time to progression was 6.7 months. The highest significant sensitivity and specificity to call the glioblastoma recurrence was observed for the total choline (tCho) to total N-acetylaspartate (tNAA) concentration ratio with the threshold ≥ 1.3 (sensitivity 100.0% and specificity 94.7%). The ADCmean value higher than 1313 × 10(- 6) mm(2)/s was associated with the pseudoprogression (sensitivity 98.3%, specificity 100.0%). The combination of MRS focused on the tCho/tNAA concentration ratio and the ADCmean value represents imaging methods applicable to early non-invasive differentiation between a glioblastoma recurrence and a pseudoprogression. However, the institutional definition and validation of thresholds for differential diagnostics is needed for the elimination of setup errors before implementation of these multimodal imaging techniques into clinical practice, as well as into clinical trials.
650    _2
$a dospělí $7 D000328
650    _2
$a senioři $7 D000368
650    _2
$a kyselina asparagová $x analogy a deriváty $x metabolismus $7 D001224
650    _2
$a nádory mozku $x diagnostické zobrazování $7 D001932
650    _2
$a cholin $x metabolismus $7 D002794
650    _2
$a kohortové studie $7 D015331
650    12
$a difuzní magnetická rezonance $7 D038524
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a glioblastom $x diagnostické zobrazování $7 D005909
650    _2
$a kyselina glutamová $x metabolismus $7 D018698
650    _2
$a lidé $7 D006801
650    _2
$a počítačové zpracování obrazu $7 D007091
650    12
$a magnetická rezonanční spektroskopie $7 D009682
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a ROC křivka $7 D012372
650    _2
$a neparametrická statistika $7 D018709
655    _2
$a časopisecké články $7 D016428
655    _2
$a práce podpořená grantem $7 D013485
700    1_
$a Bulik, Martin $u International Clinical Research Center, St. Anne's University Hospital Brno, 656 91 Brno, Czech Republic; Department of Diagnostic Imaging, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic; Department of Diagnostic Imaging, St. Anne's University Hospital Brno, 656 91 Brno, Czech Republic. $7 xx0323843
700    1_
$a Pospíšil, Petr $u Department of Radiation Oncology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic; Department of Radiation Oncology, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic. $7 xx0173603
700    1_
$a Lakomý, Radek $u Department of Comprehensive Cancer Care, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic; Department of Comprehensive Cancer Care, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic. $7 xx0164218
700    1_
$a Smrčka, Martin, $u Department of Neurosurgery, University Hospital Brno, Brno 625 00, Czech Republic. $d 1965- $7 xx0000301
700    1_
$a Šlampa, Pavel, $u Department of Radiation Oncology, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic; Department of Radiation Oncology, Masaryk Memorial Cancer Institute, 656 53 Brno, Czech Republic. $d 1960- $7 mzk2004257405
700    1_
$a Jančálek, Radim, $u Department of Neurosurgery, St. Anne's University Hospital Brno, Faculty of Medicine, Masaryk University, 625 00 Brno, Czech Republic; Department of Neurosurgery, St. Anne's University Hospital Brno, 656 91 Brno, Czech Republic. $d 1975- $7 xx0037113
773    0_
$w MED00188130 $t NeuroImage. Clinical $x 2213-1582 $g Roč. 11 (20160226), s. 316-321
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27298760 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20180515 $b ABA008
991    __
$a 20241016141524 $b ABA008
999    __
$a ok $b bmc $g 1300831 $s 1014047
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 11 $c - $d 316-321 $e 20160226 $i 2213-1582 $m NeuroImage. Clinical $n Neuroimage Clin $x MED00188130
GRA    __
$a NT14120 $p MZ0
GRA    __
$a NT14600 $p MZ0
LZP    __
$a Pubmed-20180515

Find record

Citation metrics

Archiving options